CEO Protopapas retires; Dr. Martin Huber takes over; CMO Dr. Arvin Yang departs

Mersana Therapeutics, Inc.

CEO Anna Protopapas retires effective Sept 10; remains on board; receives prorated 2023 bonus and extended equity vesting.
Dr. Martin Huber appointed President & CEO effective Sept 11; base salary $625K, target bonus 60%, option for 1M shares, RSU for 667K shares.
CMO Dr. Arvin Yang last day Sept 29; severance of 9 months base salary plus COBRA premiums.
Brian DeSchuytner named SVP, COO & CFO; Mohan Bala named SVP, Chief Development Officer; Ashish Mandelia VP, Chief Accounting Officer.
Compensation Committee granted 330,000 RSUs as retention awards to senior management, vesting Oct 1, 2024.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin Huber

President and Chief Executive Officer

Mersana Therapeutics, Inc.

Effective: 2023-09-11
Filed: September 6, 2023, 7:59 PM ET

Martin Huber, M.D., was appointed as the Company’s President and Chief Executive Officer, effective as of September 11, 2023

Departed

Anna Protopapas

President and Chief Executive Officer

Mersana Therapeutics, Inc.

Effective: 2023-09-10
Successor: Martin Huber, M.D.
Filed: September 6, 2023, 7:59 PM ET

Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, Inc. (the “Company”), provided the Company with notice of her desire and intention to retire, and on September 6, 2023, the Company announced Ms. Protopapas’ retirement effective as of September 10, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Huber was appointed as President and Chief Executive Officer at Mersana Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Martin Huber, M.D., was appointed as the Company’s President and Chief Executive Officer, effective as of September 11, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anna Protopapas retired as President and Chief Executive Officer at Mersana Therapeutics, Inc..

Action: retired
Role: President and Chief Executive Officer

Exact text from the filing

Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, Inc. (the “Company”), provided the Company with notice of her desire and intention to retire, and on September 6, 2023, the Company announced Ms. Protopapas’ retirement effective as of September 10, 2023

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-098499

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.